1. Total anomalous pulmonary venous connection: Influence of heterotaxy and venous obstruction on outcomes
- Author
-
Edward Hickey, Christopher A. Caldarone, Evan E. Edmunds, Ziyad M. Binsalamah, Zachary A. Spigel, and Jeffrey S. Heinle
- Subjects
Male ,Reoperation ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Time Factors ,Heterotaxy Syndrome ,030204 cardiovascular system & hematology ,Single Center ,Pulmonary vein ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Recurrence ,Internal medicine ,Humans ,Medicine ,Total anomalous pulmonary venous connection ,Retrospective Studies ,business.industry ,Scimitar Syndrome ,medicine.disease ,Venous Obstruction ,Confidence interval ,Treatment Outcome ,030228 respiratory system ,Pulmonary Veins ,Single ventricle physiology ,Cardiology ,Pulmonary Veno-Occlusive Disease ,Female ,Surgery ,Cardiology and Cardiovascular Medicine ,business ,Vascular Surgical Procedures ,Heterotaxy - Abstract
Previous studies have demonstrated increased early mortality and pulmonary vein reintervention for patients with total anomalous pulmonary venous connection (TAPVC) and heterotaxy syndrome (HTX+) compared with patients with TAPVC without heterotaxy syndrome (HTX-). We aimed to evaluate the longitudinal risk of pulmonary vein reintervention and mortality in HTX + patients.A retrospective review was performed to identify longitudinal interventions in patients with TAPVC seen at a single center from 1995 to 2019. The mean cumulative interventions were described for all patients using the Nelson-Aalen estimator. Survival with TAPVC was described using Kaplan-Meier estimates.A total of 336 patients were identified with TAPVC, of whom 118 (35%) had heterotaxy syndrome. Functional single ventricles were identified in 106 of these 118 HTX + patients (90%) and in 14 of 218 HTX- patients (6%) (P .001). Obstructed TAPVC (OBS+) was present in 49 of 118 HTX + patients (42%) and in 87 of 218 HTX- patients (40%) (P = .89). The median duration of follow-up was 6.5 years. Five-year survival was 69% for HTX+/OBS + patients, 72% for HTX+/OBS- patients, 86% for HTX-/OBS + patients, and 95% for HTX-/OBS- patients (P .0001, log-rank test). The mean number of pulmonary vein interventions at the median follow-up time was greater in the HTX+/OBS + patients compared with HTX+/OBS- patients (mean, 2.0 vs 1.1; P = .030), HTX-/OBS + patients (mean, 1.3; P = .033), and HTX-/OBS- patients (mean, 1.3; P = .029).Among the 4 cohorts, HTX+ was associated with a higher rate of mortality, and HTX+/OBS+ was associated with a greater number of pulmonary vein interventions. This may be due in part to the high prevalence of single ventricle physiology in the HTX + cohort.
- Published
- 2022
- Full Text
- View/download PDF